We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

By LabMedica International staff writers
Posted on 06 Jun 2023
Print article
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels. These tests are essential in identifying type 1, type 2, and pre-diabetes, as well as managing ongoing diabetes. For diabetic individuals, monitoring HbA1c levels in the blood aids in the long-term tracking of blood glucose levels. The rising prevalence of diabetes and other lifestyle diseases is expected to drive the growth of the HbA1c testing devices market. Additionally, increased focus on preventive care and greater accuracy of HbA1c testing devices in diagnosing diabetes are expected to further contribute to market growth. However, the elevated cost of HbA1c laboratory testing may inhibit this growth. Hence, the global HbA1c testing devices market is projected to expand at a CAGR of 10.3%, from USD 1.72 billion in 2023 to USD 2.56 billion in 2027.

These are the latest findings of Research and Markets (Dublin, Ireland), a provider of market research reports and data.

The two main types of HbA1c testing devices are benchtop and handheld devices. Benchtop HbA1c testing devices, designed for ease of use on a laboratory bench, are utilized in laboratories to test patients' blood sugar levels. The advancement of HbA1c testing devices, such as point-of-care testing (POCT) and handheld devices, has simplified diabetes monitoring for both patients and healthcare professionals. These devices provide speedy and precise results, reducing reliance on conventional lab-based testing. The HbA1c testing devices market consists of automated, semi-automated, and bio-sensor-based instruments. The advent of cost-effective HbA1c tests and devices is expected to propel market growth. Various methods used to measure HbA1c include ion-exchange chromatography, electrophoretic methods, mass spectroscopy, reversed-phase HPLC, and electrospray iontophoresis, employed in hospitals, pharmaceuticals, medical devices, and laboratory testing.

The high rate of undiagnosed diabetes in emerging economies presents promising growth opportunities for the HbA1c testing devices market. Regionally, North America dominated the global HbA1c testing devices market in 2022. The growth of the HbA1c testing devices market in Europe is expected to be driven by increased product awareness and higher adoption of tests in countries such as Germany, France, and the UK. However, Asia-Pacific is projected to be the fastest-growing market for HbA1c testing devices during the forecast period, due to the evolving healthcare infrastructure in countries like China and India, as well as the rapidly rising incidence of diabetes in the region.

Related Links:
Research and Markets 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.